During the 1-month IT due diligence at the beginning of the year, digatus subjected the target company’s IT landscape to a thorough examination, including:
- Analysis of the current IT situation
- Development of a potential IT target vision
- Cost, investment, and risk assessment
- Review of compatibility and integration possibilities for applications
Infrareal Holding will take over the 24-hectare property including buildings and infrastructure facilities, as well as some pharmaceutical production plants. The site in Orth, Austria, is a center of excellence for the pharmaceutical and life science industry, focusing on gene and cell therapy as well as biologics. Infrareal intends to use its long-standing experience in operating pharmaceutical sites to expand and further develop the location. In doing so, the company is pursuing its announced strategy to become one of the leading operators of pharmaceutical and biotech sites in German-speaking countries.
About Infrareal Holding GmbH & Co. KG
Infrareal employs over 800 people and specializes in the operation and development of pharma parks with a focus on pharmaceuticals, biotechnology, and life sciences. To this end, new industrial parks, pharma parks, real estate, and infrastructure are acquired to operate highly complex multi-user sites. It is particularly important to Infrareal to create long-term perspectives for the respective locations. The company currently operates more than 250 buildings and facilities.
Robert Mair
With over 17 years of professional experience in the IT industry, Robert Mair has developed comprehensive expertise across a wide range of functions and sectors. His profound knowledge in managing international and national projects, as well as leading hybrid teams, gives him a deep understanding of steering and successfully completing challenging projects in time-critical customer situations. In his role as Principal at digatus, he primarily contributes his expertise in the areas of IT Mergers & Acquisitions and IT Transformation.
